Literature DB >> 11054231

Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi.

M Waltham1, K G Burnand, M Collins, A Smith.   

Abstract

OBJECTIVE: Resolution of venous thrombi is accompanied by an ingrowth of capillaries, which appears to be analogous to angiogenesis in other tissues. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are major regulators of angiogenesis. The aim of this study was to determine the temporal changes and the location of VEGF and bFGF expression in a rat model of venous thrombus resolution. DESIGN AND METHODS: Thrombi were induced in the inferior venae cavae of rats by creating a stenosis to reduce blood flow by 80% to 90%. Thrombi, adjacent inferior vena cava wall, and systemic blood were collected at 1, 3, 7, 14, 21, and 28 days after thrombus generation (n = 9). Sham operations were performed (n = 5), and blood was collected at 1, 3, and 7 days. VEGF and bFGF were measured with specific immunoassays, and levels in tissues were expressed as picogram per milligram soluble protein. Tissues from two animals that were humanely killed 7 days after thrombus formation were prepared for histological examination. Immunohistochemistry was performed by the use of antibodies against VEGF, bFGF, and ED-1 (a monocyte/macrophage marker).
RESULTS: Laminated thrombi were reliably produced with a median weight at 1 day of 39 mg (range, 23-63 mg). There was a significant increase in thrombus VEGF concentration between 1 day (median, 247; range, 0-514) and 7 days (median, 556; range, 254-1741) (P =.02). There was no difference between the seventh day and subsequent days. There was a positive linear correlation between thrombus bFGF concentration and time (R = 0.74, P <.0001), with a more than 300-fold increase in bFGF concentration over the 28 days of the study. VEGF and bFGF concentrations in the adjacent vena caval wall did not change significantly with time. The serum VEGF was significantly raised at 1 day (median, 5520 pg/mL; range, 4040-7912 pg/mL) and 3 days (median, 3880 pg/mL; range, 2564-7232 pg/mL) compared with 7 days (median, 1790 pg/mL; range, 232-3228 pg/mL) (P <.0001). Similar changes in the serum VEGF also developed in the sham-operated animals. The serum bFGF (day 1 median, 15.5 pg/mL; range, 1-42 pg/mL) did not change with time. Immunohistochemistry showed that the VEGF antigen was localized to monocytes, endothelial cells, and spindle-shaped cells within the thrombus. The bFGF antigen was localized to mononuclear cells and spindle-shaped cells and was also present in the extracellular matrix.
CONCLUSION: VEGF and bFGF are found in organizing thrombi and have characteristic temporal expression patterns, which suggest that they have a role in thrombus resolution. Augmenting angiogenic growth factor expression may enhance thrombus recanalization, thus reducing long-term complications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11054231     DOI: 10.1067/mva.2000.110882

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  11 in total

Review 1.  Approach to chemotherapy-associated thrombosis.

Authors:  Peter Oppelt; Anthony Betbadal; Lalitha Nayak
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

2.  Absence of IFN-γ accelerates thrombus resolution through enhanced MMP-9 and VEGF expression in mice.

Authors:  Mizuho Nosaka; Yuko Ishida; Akihiko Kimura; Yumi Kuninaka; Masanori Inui; Naofumi Mukaida; Toshikazu Kondo
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

Review 3.  Impact of thrombosis on pulmonary endothelial injury and repair following sepsis.

Authors:  Colin E Evans; You-Yang Zhao
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-27       Impact factor: 5.464

Review 4.  Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives.

Authors:  Jeng-Jiann Chiu; Shu Chien
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 5.  The Dural AV-Fistula (DAVF), the Most Frequent Acquired Vascular Malformation of the Central Nervous System (CNS).

Authors:  I Wanke; D A Rüfenacht
Journal:  Clin Neuroradiol       Date:  2015-08-26       Impact factor: 3.649

Review 6.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

7.  Upregulation of hypoxia-inducible factor 1 alpha in local vein wall is associated with enhanced venous thrombus resolution.

Authors:  Colin E Evans; Julia Humphries; Matthew Waltham; Prakash Saha; Katherine Mattock; Ashish Patel; Anwar Ahmad; Ashar Wadoodi; Bijan Modarai; Kevin Burnand; Alberto Smith
Journal:  Thromb Res       Date:  2011-05-31       Impact factor: 3.944

8.  Adventitial Progenitor Cells of Human Great Saphenous Vein Enhance the Resolution of Venous Thrombosis via Neovascularization.

Authors:  Siying Ling; Zhen Ma; Yong Teng; Xuemei Jiang; Junning Cheng; Ruihao Li; Mingyi Zhang; Hailong Luo; Yikuan Chen
Journal:  Stem Cells Int       Date:  2021-02-23       Impact factor: 5.443

9.  Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor.

Authors:  Derek Klarin; Connor A Emdin; Pradeep Natarajan; Mark F Conrad; Sekar Kathiresan
Journal:  Circ Cardiovasc Genet       Date:  2017-04

10.  Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension.

Authors:  Sherin Alias; Bassam Redwan; Adelheid Panzenboeck; Max P Winter; Uwe Schubert; Robert Voswinckel; Maria K Frey; Johannes Jakowitsch; Arman Alimohammadi; Lukas Hobohm; Andreas Mangold; Helga Bergmeister; Maria Sibilia; Erwin F Wagner; Eckhard Mayer; Walter Klepetko; Thomas J Hoelzenbein; Klaus T Preissner; Irene M Lang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-13       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.